Evidence map›Paper›PMID 28560410›Full record

ArticleInternational journal of oncology2017

DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.

Hui Wang, Yu-Yuan Dai, Wen-Qian Zhang, Ping-Chih Hsu, Yi-Lin Yang, Yu-Cheng Wang, Geraldine Chan, Alfred Au, Zhi-Dong Xu, Shu-Juan Jiang and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Pleiotropic effects of DCLK1 in cancer and cancer stem cells.Frontiers in molecular biosciences · 2022
    Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Hui WangDepartment of Pulmonary Medicine, Affiliated Shandong Provincial Hospital, Shandong University, Shandong, P.R. China.
Yu-Yuan DaiThoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Wen-Qian ZhangThoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Ping-Chih HsuThoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Yi-Lin YangThoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Yu-Cheng WangThoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Geraldine ChanThoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Alfred AuDivision of Diagnostic Pathology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Zhi-Dong XuThoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Shu-Juan JiangDepartment of Pulmonary Medicine, Affiliated Shandong Provincial Hospital, Shandong University, Shandong, P.R. China.
Wei WangDepartment of Respiratory Medicine, The Second Hospital of Shandong University, Shandong, P.R. China.
David M JablonsThoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Liang YouThoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
UCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of California, San Francisco · USShandong Provincial Hospital · CNSecond Hospital of Shandong University · CN

Funding

The Role of Cul4A in Genome Stability and Cancer DevelopmentR01CA140654 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YOU, LIANG · 2010 to 2014
$1.5M
NCI NIH HHS R01 CA140654
6 · The paper itself

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive cancer for which more effective treatments are needed. In this study, strong to moderate staining of MET and ERK5 was detected in 67.1 and 48% of the analyzed 73 human mesothelioma tumors, and significant correlation of MET and ERK5 expression was identified (P<0.05). We evaluated the doublecortin-like kinase 1 (DCLK1) expression in human mesothelioma tumors. Our results showed that 50.7% of the immunohistochemistry analyzed human mesothelioma tumors have strong to moderate staining of DCLK1, and its expression is significantly correlated with MET or ERK5 expression (P<0.05). Also, the upregulation of DCLK1 is correlated with poor prognosis in MPM patients (P=0.0235). To investigate whether DCLK1 is downstream of MET/ERK5 signaling in human mesothelioma, the effect of DCLK1 expression was analyzed after treatments with either the MET inhibitor XL184 or the ERK5 inhibitor XMD8-92 in human mesothelioma cell lines. Our results showed that the MET inhibitor XL184 reduced the expression of phospho‑ERK5 and DCLK1 expression in human mesothelioma cell lines. In addition, the ERK5 inhibitor XMD8-92 reduced the expression of phospho-ERK5 and DCLK1 expression in human mesothelioma cell lines. Furthermore, XML184 and XMD8-92 treatment impaired invasion and tumor sphere formation ability of H290 mesothelioma cells. These results suggest that DCLK1 is regulated by MET/ERK5 signaling in human mesothelioma, and the MET/ERK5/DCLK1 signaling cascade could be further developed into a promising therapeutic target against mesothelioma.

Indexed as

AgedApoptosisBiomarkers, TumorCell MovementCell ProliferationDoublecortin-Like KinasesFemaleFollow-Up StudiesHumansIntracellular Signaling Peptides and ProteinsLung NeoplasmsMaleMesotheliomaMesothelioma, MalignantMitogen-Activated Protein Kinase 7Pleural NeoplasmsBiomarkers, TumorDCLK1 protein, humanDoublecortin-Like KinasesIntracellular Signaling Peptides and ProteinsMET protein, humanMitogen-Activated Protein Kinase 7Protein Serine-Threonine KinasesProto-Oncogene Proteins c-met

Identifiers

PMID28560410
PMCPMC5467791
OpenAlexW2619969047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.